Last checked at 
Oxford BioDynamics PLC - biotechnology firm focused on discovery and development of epigenetic biomarkers - Revenue for financial year ended September 30 falls to GBP341,000 from GBP456,000 the year before, with pretax loss widening to GBP7.6 million from GBP4.9 million. Staff costs rise to GBP3.8 million from GBP2.7 million, and depreciation & amortisation charge more than doubles to GBP1.1 million from GBP467,000. Says it achieved progress in year, with launch of first products and expansion of its UK and US infrastructure. Business is "well positioned for commercial success" in 2022. "I firmly believe that in 2022 we will begin to see rewards for the hard work that has been done and I look forward to updating shareholders as the year progresses," says Chief Executive Jon Burrows.
Current stock price: 27.15 pence, down 8.0% on Tuesday
12-month change: down 66%
By Lucy Heming; lucyheming@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
